v3.26.1
BASIS OF PRESENTATION (Details 1) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Product Information [Line Items]    
Total revenue $ 32,427,936 $ 26,622,324
Total cost of goods sold (18,281,254) (13,379,346)
Gross profit 14,146,682 13,242,978
Operating expenses    
Amortization 702,258 993,379
General and administration 11,643,917 10,580,794
Share-based compensation 2,393,994 1,608,823
Total operating expenses 14,740,169 13,182,996
Other income (expense)    
Interest expense (150,331) (77,513)
Other income 932,730 1,090,649
Interest income 179,731 350,656
Unrealized gain (loss) on derivative liability 44,917 (7,754,402)
Unrealized gain on warrant asset 247,477 3,094,413
Realized loss on warrant liability (1,741,710)
Loss on equity investment in associate (452,962) (251,230)
Total other income (expense), net 5,426,883 (12,174,786)
Loss before income tax expense 4,833,396 (12,114,804)
Income tax expense (1,603,439) (3,864,547)
Net loss 3,229,957 (15,979,351)
Currency translation adjustment 4,024 (17,861)
Total comprehensive loss 3,233,981 (15,997,212)
Net loss for the period attributable to:    
Non-controlling interest (1,500,152) (27,028)
Comprehensive income (loss) for the period attributable to:    
Shareholders (1,733,829) 16,024,240
Non-controlling interest (1,500,152) (27,028)
Total comprehensive income (loss) 3,233,981 (15,997,212)
IFRS [Member]    
Product Information [Line Items]    
Total revenue   27,017,265
Total cost of goods sold   (13,033,710)
Gross profit, excluding fair value items   13,983,555
Realized fair value loss amounts in inventory sold   (3,358,862)
Unrealized fair value gain amounts on growth of biological assets   2,816,943
Gross profit   13,441,636
Operating expenses    
Amortization   939,727
General and administration   10,075,360
Share-based compensation   1,306,607
Total operating expenses   12,321,694
Income from operations   1,119,942
Other income (expense)    
Interest expense   (379,161)
Accretion expense   (2,042,556)
Other income   1,938,713
Interest income  
Gain on extinguishment of notes receivable   156,165
Unrealized gain (loss) on derivative liability   (12,768,905)
Realized loss on derivative liability  
Unrealized gain on warrant asset   3,094,413
Realized loss on warrant liability  
Loss on equity investment in associate   (169,637)
Loss on disposal of property, plant and equipment   50,057
Total other income (expense), net   (10,120,911)
Loss before income tax expense   (9,000,969)
Income tax expense   (1,695,825)
Net loss   (10,696,794)
Currency translation adjustment   (17,861)
Total comprehensive loss   (10,714,655)
Net loss for the period attributable to:    
Shareholders   (11,303,642)
Non-controlling interest   606,848
Net loss   (10,696,794)
Comprehensive income (loss) for the period attributable to:    
Shareholders   (11,321,503)
Non-controlling interest   606,848
Total comprehensive income (loss)   (10,714,655)
Effect of transition to U.S. GAAP [Member]    
Product Information [Line Items]    
Total revenue   (394,941)
Total cost of goods sold   (345,636)
Gross profit, excluding fair value items   (740,577)
Realized fair value loss amounts in inventory sold   3,358,862
Unrealized fair value gain amounts on growth of biological assets   (2,816,943)
Gross profit   (198,658)
Operating expenses    
Amortization   53,652
General and administration   505,434
Share-based compensation   302,216
Total operating expenses   861,302
Income from operations   (1,059,960)
Other income (expense)    
Interest expense   301,648
Accretion expense   206,116
Other income   (848,064)
Interest income   350,656
Gain on extinguishment of notes receivable   (156,165)
Unrealized gain (loss) on derivative liability   5,014,503
Realized loss on derivative liability   (5,049,209)
Unrealized gain on warrant asset  
Realized loss on warrant liability   (1,741,710)
Loss on equity investment in associate   (81,593)
Loss on disposal of property, plant and equipment   (50,057)
Total other income (expense), net   (2,053,875)
Loss before income tax expense   (3,113,835)
Income tax expense   (2,168,722)
Net loss   (5,282,557)
Currency translation adjustment  
Total comprehensive loss   (5,282,557)
Net loss for the period attributable to:    
Shareholders   (4,702,737)
Non-controlling interest   (579,820)
Net loss   (5,282,557)
Comprehensive income (loss) for the period attributable to:    
Shareholders   (4,702,737)
Non-controlling interest   (579,820)
Total comprehensive income (loss)   (5,282,557)
U.S. GAAP [Member]    
Product Information [Line Items]    
Total revenue   26,622,324
Total cost of goods sold   (13,379,346)
Gross profit, excluding fair value items   13,242,978
Realized fair value loss amounts in inventory sold  
Unrealized fair value gain amounts on growth of biological assets  
Gross profit   13,242,978
Operating expenses    
Amortization   993,379
General and administration   10,580,794
Share-based compensation   1,608,823
Total operating expenses   13,182,996
Income from operations   59,982
Other income (expense)    
Interest expense   (77,513)
Accretion expense   (1,836,440)
Other income   1,090,649
Interest income   350,656
Gain on extinguishment of notes receivable  
Unrealized gain (loss) on derivative liability   (7,754,402)
Realized loss on derivative liability   (5,049,209)
Unrealized gain on warrant asset   3,094,413
Realized loss on warrant liability   (1,741,710)
Loss on equity investment in associate   (251,230)
Loss on disposal of property, plant and equipment  
Total other income (expense), net   (12,174,786)
Loss before income tax expense   (12,114,804)
Income tax expense   (3,864,547)
Net loss   (15,979,351)
Currency translation adjustment   (17,861)
Total comprehensive loss   (15,997,212)
Net loss for the period attributable to:    
Shareholders   (16,006,379)
Non-controlling interest   27,028
Net loss   (15,979,351)
Comprehensive income (loss) for the period attributable to:    
Shareholders   (16,024,240)
Non-controlling interest   27,028
Total comprehensive income (loss)   (15,997,212)
Product [Member]    
Product Information [Line Items]    
Total revenue 32,427,936 25,364,193
Product [Member] | IFRS [Member]    
Product Information [Line Items]    
Total revenue   25,029,634
Product [Member] | Effect of transition to U.S. GAAP [Member]    
Product Information [Line Items]    
Total revenue   334,559
Product [Member] | U.S. GAAP [Member]    
Product Information [Line Items]    
Total revenue   25,364,193
Service [Member]    
Product Information [Line Items]    
Total revenue 1,258,131
Service [Member] | IFRS [Member]    
Product Information [Line Items]    
Total revenue   1,987,631
Service [Member] | Effect of transition to U.S. GAAP [Member]    
Product Information [Line Items]    
Total revenue   (729,500)
Service [Member] | U.S. GAAP [Member]    
Product Information [Line Items]    
Total revenue   1,258,131
Cost of finished cannabis inventory sold [Member]    
Product Information [Line Items]    
Total cost of goods sold (18,281,254) (13,172,677)
Cost of finished cannabis inventory sold [Member] | IFRS [Member]    
Product Information [Line Items]    
Total cost of goods sold   (12,827,041)
Cost of finished cannabis inventory sold [Member] | Effect of transition to U.S. GAAP [Member]    
Product Information [Line Items]    
Total cost of goods sold   (13,172,677)
Cost of finished cannabis inventory sold [Member] | U.S. GAAP [Member]    
Product Information [Line Items]    
Total cost of goods sold   (206,669)
Costs of service revenue [Member]    
Product Information [Line Items]    
Total cost of goods sold (206,669)
Costs of service revenue [Member] | IFRS [Member]    
Product Information [Line Items]    
Total cost of goods sold   (345,636)
Costs of service revenue [Member] | Effect of transition to U.S. GAAP [Member]    
Product Information [Line Items]    
Total cost of goods sold  
Costs of service revenue [Member] | U.S. GAAP [Member]    
Product Information [Line Items]    
Total cost of goods sold   $ (206,669)